Stockreport

Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals, Ltd. - American Depositary Shares  (QNRX) 
PDF Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US Orphan Drug Designation previously granted by the European Medicines Agen [Read more]